Abstract
For half a century, successful antifolate therapy against Plasmodium falciparum malaria has been attributed to host-parasite differences in drug binding to dihydrofolate reductase–thymidylate synthase (DHFR-TS). Selectivity may also arise through previously unappreciated differences in regulation of this drug target. The DHFR-TS of Plasmodium binds its cognate messenger RNA (mRNA) and inhibits its own translation. However, unlike translational regulation of DHFR or TS in humans, DHFR-TS mRNA binding is not coupled to enzyme active sites. Thus, antifolate treatment does not relieve translational inhibition and parasites cannot replenish dead enzyme.
Malaria caused by various species of protozoan parasites, Plasmodium, results in about 900 million acute cases and 2.7 million deaths every year (1). With the emergence of drug resistance, there is a continual need for new antimalarial agents that are potent and selective. Development of new drugs will be greatly facilitated by a complete understanding of the molecular mechanisms underlying previously successful antimalarials. Antifolates, including pyrimethamine, have been used in the treatment of malaria for about 50 years (2). These drugs target DHFR-TS, a specific bifunctional protein in the parasite (3). DHFR and TS are expressed as separate proteins in mammalian cells, but the functional importance, if any, of the difference seen in the protein configuration has remained elusive.
The selective activity of pyrimethamine has traditionally been attributed to higher affinity of the drug for Plasmodium DHFR-TS than for human DHFR (2, 4–6). However, other DHFR-TS inhibitors, which lack parasite-specific affinity, also show selective toxicity for malaria (7–9). WR99210 is a potent inhibitor of P. falciparum proliferation in culture (median inhibitory concentration IC50 = 0.1 nM; Fig. 1A) (9, 10). In contrast, human fibroblast HT1080 cells tolerate this compound (IC50 = 6300 nM; Fig. 1A) (10). The large difference in sensitivity to WR99210 is not due to differential affinity for DHFR: Enzyme kinetic assays revealed a mere 10-fold difference in binding of WR99210 between Plasmodium DHFR-TS (inhibition constant Ki = 1.1 nM) and human DHFR (Ki = 12 nM) (10). Integration of one human DHFR coding sequence in P. falciparum is sufficient to shift the IC50 of WR99210 from 0.1 nm to 860 nM, as previously reported (11, 12). This degree of resistance is similar to that of human cells (Fig. 1A). Thus, WR99210 selectivity does not arise from host-parasite differences in drug uptake, metabolism, or export.
Host-parasite differences in the regulation and expression of DHFR and TS may play a role in drug selectivity. Mammalian DHFR and TS levels increase with specific drug treatment (13–15): Methotrexate causes accumulation of DHFR protein (13), and 5-fluorouracil and D1694 increase TS levels (15, 16). Translational control determines such drug-induced target overproduction in mammalian cells. In the absence of substrates or drugs, mammalian DHFR and TS bind their cognate mRNA within the coding region and block translation (16–18). In the presence of substrates [dihydrofolate (DHF) and the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) for DHFR; deoxyuridine monophosphate (dUMP) and 5,10-methylenetetrahydrofolate (mTHF) for TS] or inhibitors [methotrexate for DHFR; 5-fluoro-dUMP (FdUMP) for TS], the host enzymes disassociate from their cognate mRNA, relieving translational arrest (16–18). Thus, drug treatment reverses natural, autologous, translational inhibition and causes overproduction of the target protein. Such innate cellular buffering ensures that mammalian cells are resistant to inhibitors of DHFR and TS. The absence of such cellular buffering may account for the sensitivity of Plasmodium to DHFR-TS inhibitors.
Like the mammalian enzymes, Plasmodium DHFR-TS specifically blocked its own synthesis (Fig. 1B). An in vitro translation system synthesized the expected 70-kD protein (8) from Plasmodium DHFR-TS mRNA. Purified Plasmodium DHFR-TS protein prevented translation of DHFR-TS mRNA but not the translation of mRNA for brome mosaic virus (BMV ) (Fig. 1B). Gel-shift assay showed direct binding of full-length Plasmodium DHFR-TS to its cognate mRNA but not to the unrelated gene10 mRNA from bacteriophage T7 (Fig. 1C). Binding of labeled DHFR-TS mRNA was reversed with nonlabeled DHFR-TS mRNA but not by nonspecific T7 gene10 mRNA.
Closer examination revealed important differences between the regulation of Plasmodium and mammalian DHFRs. In contrast to mammalian DHFR, catalytically active Plasmodium DHFR domain failed to bind DHFR mRNA or DHFR-TS mRNA (Fig. 1C, lanes 6 and 7). To determine whether the receptor for Plasmodium DHFR-TS mRNA lay outside the DHFR domain ( TS-40) (19), we used an E. coli expression system (Fig. 2A). The difficulties in heterologous expression of full-length Plasmodium DHFR-TS in E. coli are well known and are usually attributed to poor use of malaria codons (20, 21). The following results show that under-expression of full-length Plasmodium DHFR-TS is better explained by invoking RNA-protein interactions. Truncated DHFR domain of P. falciparum was readily overexpressed (Fig. 2B, lanes 2 and 5), as was a truncated TS-31 fragment (Fig. 2D, lane 4). Truncated DHFR expression with P. falciparum codons produced just as much protein as did constructs made with E. coli codons (22). In sharp contrast, full-length DHFR-TS (70 kD) was poorly expressed even though its mRNA was as abundant as that of DHFR alone in parallel E. coli cultures (Fig. 2C). Most important, overexpression of Plasmodium DHFR domain was suppressed when TS-40 was produced in trans from a separate plasmid (Fig. 2D, lane 7). The TS-40 fragment itself was poorly expressed (Fig. 2D, lane 5). These expression studies are consistent with the hypothesis that Plasmodium DHFR-TS protein binds its own RNA through a site distant from the DHFR catalytic site.
Because the DHFR domain of malaria did not bind mRNA, we hypothesized that inhibitors of DHFR would not reverse interactions between full-length Plasmodium DHFR-TS and its cognate mRNA. This proved to be the case. Inhibition of Plasmodium DHFR-TS synthesis in an in vitro translation system could not be reversed by substrates or inhibitors of DHFR-TS (Fig. 1D). Similarly, direct binding of Plasmodium DHFR-TS to its mRNA could not be reversed with substrates (NADPH and DHF for DHFR; dUMP and mTHF for TS) nor with inhibitors [methotrexate (MTX), pyrimethamine, and WR99210, which inhibit DHFR; F-dUMP and 1843U89, which inhibit TS)] (Fig. 1E). The drug binding studies show directly that, unlike the host enzymes, the bifunctional Plasmodium protein binds mRNA at a site distinct from the DHFR as well as the TS catalytic site.
Together, these results predicted that WR99210 treatment of intact cells would induce overexpression of mammalian DHFR but not Plasmodium DHFR-TS. This prediction was tested in P. falciparum cells transformed with a single copy of human DHFR (12). Even before drug treatment, the expression level of human DHFR was higher than that of Plasmodium DHFR-TS by a factor of ~6 (Fig. 3A). After treatment with 500 nM WR99210, there was another factor of ~6 increase in human DHFR protein but no change in Plasmodium DHFR-TS (Fig. 3A). Even though human DHFR protein expression increased, the levels of human DHFR mRNA and Plasmodium DHFR-TS mRNA were comparable and unchanged, before and after WR99210 treatment (Fig. 3B). No changes in degradation rates of Plasmodium DHFR-TS or human DHFR were observed during WR99210 treatment (23).
Our findings point to an important paradigm for antimicrobial drug selectivity. Relatively nonspecific antimetabolites can selectively inhibit pathogen functions if the pathogen uniquely expresses limiting quantities of the drug target and lacks a mechanism to readily replenish the inhibited target. In the Plasmodium DHFR-TS system, host-parasite differences in target levels are partially realized through intrinsic RNA-protein interactions that are insensitive to cellular metabolites in the parasite; they are fully realized after drug administration. Another drug target that shows selective sensitivity without a host-parasite difference in affinity for the inhibiting drug is the African trypanosome enzyme ornithine decarboxylase (24). During treatment with difluoromethylornithine (DFMO), selectivity is achieved, at least in part, through rapid replenishment of the host ornithine decarboxylase but not the parasite enzyme. Although increases in target expression through gene amplification are known to affect drug sensitivity (25), our studies show that host-parasite differences in cellular responses to small ligands can affect target levels and drug sensitivity. Such properties may be of interest in future searches for good drug targets.
Supplementary Material
Acknowledgments
We thank D. Fidock and T. Wellems for clone B1G9; D. Banerjee for human DHFR; E. Chu and M. Hekmat-Nejad for initiating us to RNA techniques; D. Herschlag for encouragement; and L. Hedstrom, M. Parsons, M. Gelb, and S. Tuljapurkar for reading the manuscript. Supported by NIH grants AI26912 and AI40956 and by a Burroughs Wellcome Fund New Investigator in Malaria Research Award (P.K.R.), the Keck Foundation, and the B&M Gates Foundation.
References and Notes
- 1.Breman JG, Egan A, Keusch GT. Am. J. Trop. Med. Hyg. 2001;64(suppl. 1–2):iv. doi: 10.4269/ajtmh.2001.64.iv. [DOI] [PubMed] [Google Scholar]
- 2.Hitchings GH. Clin. Pharmacol. Ther. 1960;1:570. [Google Scholar]
- 3.Garrett CE, et al. Mol. Biochem. Parasitol. 1984;11:257. doi: 10.1016/0166-6851(84)90070-7. [DOI] [PubMed] [Google Scholar]
- 4.Ferone R, Burchall JJ, Hitchings GH. Mol. Pharmacol. 1969;5:49. [PubMed] [Google Scholar]
- 5.Peterson DS, Milhouse WK, Wellems TE. Proc. Natl. Acad. Sci. U.S.A. 1990;87:3018. doi: 10.1073/pnas.87.8.3018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Foote SJ, Galatis D, Cowman AF. Proc. Natl. Acad. Sci. U.S.A. 1990;87:3014. doi: 10.1073/pnas.87.8.3014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Rathod PK, Pai N, Young R. Antimicrob. Agents Chemother. 1992;36:704. doi: 10.1128/aac.36.4.704. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Hekmat-Nejad M, Rathod PK. Antimicrob. Agents Chemother. 1996;40:1628. doi: 10.1128/aac.40.7.1628. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Canfield CJ, et al. Am. J. Trop. Med. Hyg. 1993;49:121. doi: 10.4269/ajtmh.1993.49.121. [DOI] [PubMed] [Google Scholar]
- 10.Supplementary material is available on Science Online at www.sciencemag.org/cgi/content/full/296/5567/545/DC1.
- 11.Fidock DA, Wellems TE. Proc. Natl. Acad. Sci. U.S.A. 1997;94:10931. doi: 10.1073/pnas.94.20.10931. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Fidock DA, et al. Mol. Biochem. Parasitol. 2000;110:1. doi: 10.1016/s0166-6851(00)00249-8. [DOI] [PubMed] [Google Scholar]
- 13.Bertino JR, Booth BA, Bieber AL, Cashmore A, Sartorelli AC. J. Biol. Chem. 1964;239:476. [PubMed] [Google Scholar]
- 14.Chu E, Koeller DM, Johnston PG, Zinn S, Allegra CJ. Mol. Pharmacol. 1993;43:527. [PubMed] [Google Scholar]
- 15.Keyomarsi K, Samet J, Molnar G, Pardee AB. J. Biol. Chem. 1993;268:15142. [PubMed] [Google Scholar]
- 16.Chu E, Takimoto CH, Voeller D, Grem JL, Allegra CJ. Biochemistry. 1993;32:4756. doi: 10.1021/bi00069a009. [DOI] [PubMed] [Google Scholar]
- 17.Ercikan-Abali EA, et al. Biochemistry. 1997;36:12317. doi: 10.1021/bi971026e. [DOI] [PubMed] [Google Scholar]
- 18.Chu E, et al. Proc. Natl. Acad. Sci. U.S.A. 1991;88:8977. [Google Scholar]
- 19.Shallom SJ, Zhang K, Jiang L, Rathod PK. J. Biol. Chem. 1999;274:37781. doi: 10.1074/jbc.274.53.37781. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Sano G, Morimatsu K, Horii T. Mol. Biochem. Parasitol. 1994;63:265. doi: 10.1016/0166-6851(94)90062-0. [DOI] [PubMed] [Google Scholar]
- 21.Prapunwattana P, Sirawaraporn W, Yuthavong Y, Santi DV. Mol. Biochem. Parasitol. 1996;83:93. doi: 10.1016/s0166-6851(96)02756-9. [DOI] [PubMed] [Google Scholar]
- 22.Hekmat-Nejad M, Lee PC, Rathod PK. Exp. Parasitol. 1997;85:303. doi: 10.1006/expr.1997.4145. [DOI] [PubMed] [Google Scholar]
- 23.Zhang K, Rathod PK. data not shown.
- 24.Phillips MA, Coffino P, Wang CC. J. Biol. Chem. 1988;263:17933. [PubMed] [Google Scholar]
- 25.Beverley SM. Annu. Rev. Microbiol. 1991;45:417. doi: 10.1146/annurev.mi.45.100191.002221. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.